OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giant’s CAR-T programs. The newly expanded ...

OXB announces date for Capital Markets Day and participation in upcoming investor conferences Oxford, UK – 3 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, ...

OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmes Multi-year agreement with five-year initial term and option to extend Oxford, UK – 4 ...

Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global ...

Investors attending any of the above conferences who would like to meet with OXB are welcome to contact the Company’s IR team via ir@oxb.com. Live webcasts and recordings of presentations, where ...

OXB will hold its Capital Markets Day at the London Stock Exchange Group (LSEG) headquarters on 2 June 2026. Further details, including the agenda and registration information, will be provided in due ...